Active Substance: Pioglitazone Ð Metformin hydrochloride -.
Overview
Welcome to Dwaey, specifically on GLADOS-MET 15/850 mg page.
This medicine contains an important and useful components, as it consists of
Pioglitazone Ð
Metformin hydrochloride -is available in the market in concentration
Metformin Hydrochloride + Pioglitazone
Patient w/ oedema, anaemia. Premenopausal, anovulatory women. Pregnancy. Patient Counselling This drug may cause visual disturbance, if affected, do not drive or operate machinery. Monitoring Parameters Monitor HbA1c, serum glucose; signs and symptoms of oedema or heart failure, bladder cancer; liver enzymes, haematologic parameters, renal function; vit B12 and folate if anaemia is present. Routine ophth examination. Lactation: not known if crosses into breast milk, avoid using in nursing women
Type 2 DM
Renal disease or renal dysfunction (e.g. as suggested by serum creatinine levels >1.5 mg/dl in male, >1.4 mg/dl in females or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction and septicemia.Current or history of cardiac failure, active or history of bladder cancer, Known hypersensitivity to Pioglitazone, Metformin or any other component of this combination. Acute or chronic metabolic acidosis including diabetic ketoacidosis with or without coma.
>10% Lower limb edema (2.9-11.3%),Upper respiratory infection (12-16) 1-10% Weight gain (2.9-6.7%),Diarrhea (4.8-5.8%),Nausea (3.6-5.8%),Urinary tract infection (5.3-5.8%),Dizziness (4.8-5.4%),Headache (4.6-5.3%),Sinusitis (4.4-5%),Edema (3%)
3
Pioglitazone is as a potent and highly selective agonist for the peroxisome proliferator activated receptor-gamma. Activation of these receptors promotes the production of gene products involved in lipid and glucose metabolism. It also improves insulin response to target cells witho increasing the pancreatic secretion of insulin. Metformin decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose and improves insulin sensitivity (increases peripheral glucose uptake and utilisation).
Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine. Potentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.
Information not available